Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rank in Stocks #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Share Price
$0.00047446
Market Cap
$82.80
Change (1 day)
0.00%
Change (1 year)
-98.16%
Country
FR
Trade Neovacs S.A. (ALNEV)

Category

Stock split history for Neovacs S.A. (ALNEV)
Neovacs S.A. stock (symbol: ALNEV) underwent a total of 6 stock splits.
The most recent stock split occurred on Jul 18, 2025.
One ALNEV share bought prior to Feb 01, 2022 would equal to 1.5625E-23 ALNEV shares today.
Stock split list
Year Split Multiple Cumulative Multiple
2025-07-18 1:1000 x0.001 x1.5625E-23
2024-12-05 1:10000 x0.0001 x1.5625E-20
2024-02-06 1:10000 x0.0001 x1.5625E-16
2023-06-05 1:8000 x0.000125 x1.5625E-12
2023-06-02 1:8000 x0.000125 x1.25E-8
2022-02-01 1:10000 x0.0001 x0.0001
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
5 x199
DK
1 x2
US
0 -
US
0 -
BE
0 -
NL